US Bancorp DE reduced its position in shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) by 7.5% during the second quarter, according to its most recent filing with the SEC. The fund owned 87,000 shares of the biopharmaceutical company’s stock after selling 7,100 shares during the period. US Bancorp DE owned approximately 0.08% of Juno Therapeutics worth $2,600,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. M&T Bank Corp bought a new position in shares of Juno Therapeutics during the first quarter worth about $381,000. Norges Bank bought a new position in shares of Juno Therapeutics during the fourth quarter worth about $13,993,000. Nisa Investment Advisors LLC bought a new position in shares of Juno Therapeutics during the first quarter worth about $200,000. Laurion Capital Management LP bought a new position in shares of Juno Therapeutics during the first quarter worth about $390,000. Finally, BB Biotech AG boosted its position in shares of Juno Therapeutics by 16.8% in the first quarter. BB Biotech AG now owns 2,185,000 shares of the biopharmaceutical company’s stock worth $48,485,000 after buying an additional 315,000 shares during the period. 65.03% of the stock is currently owned by institutional investors and hedge funds.
Shares of Juno Therapeutics, Inc. (JUNO) opened at 26.99 on Friday. The company’s market capitalization is $2.83 billion. The company has a 50 day moving average price of $28.75 and a 200 day moving average price of $24.87. Juno Therapeutics, Inc. has a 1-year low of $17.52 and a 1-year high of $34.35.
Juno Therapeutics (NASDAQ:JUNO) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.72) by $0.24. The firm had revenue of $21.30 million for the quarter, compared to the consensus estimate of $15.59 million. Juno Therapeutics had a negative net margin of 354.36% and a negative return on equity of 27.10%. The business’s revenue for the quarter was down 22.8% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.64) earnings per share. Equities analysts predict that Juno Therapeutics, Inc. will post ($3.13) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “US Bancorp DE Sells 7,100 Shares of Juno Therapeutics, Inc. (NASDAQ:JUNO)” was published by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://www.com-unik.info/2017/08/19/us-bancorp-de-sells-7100-shares-of-juno-therapeutics-inc-nasdaqjuno-updated-updated.html.
JUNO has been the topic of a number of recent research reports. Vetr raised Juno Therapeutics to a “buy” rating in a research note on Tuesday, May 23rd. BidaskClub raised Juno Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, June 20th. Zacks Investment Research raised Juno Therapeutics from a “hold” rating to a “buy” rating and set a $32.00 price objective on the stock in a research note on Tuesday, July 11th. Morgan Stanley reduced their price objective on Juno Therapeutics from $27.00 to $26.00 and set an “equal weight” rating on the stock in a research note on Monday, May 8th. Finally, FBR & Co reaffirmed a “hold” rating on shares of Juno Therapeutics in a research note on Thursday, May 18th. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating and seven have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $30.63.
In related news, Director Anthony B. Evnin bought 9,000 shares of the company’s stock in a transaction on Tuesday, June 20th. The shares were acquired at an average cost of $24.40 per share, for a total transaction of $219,600.00. Following the purchase, the director now directly owns 66,301 shares of the company’s stock, valued at $1,617,744.40. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Jay T. Flatley bought 20,000 shares of the company’s stock in a transaction on Friday, May 26th. The stock was bought at an average price of $24.76 per share, for a total transaction of $495,200.00. The disclosure for this purchase can be found here. Insiders have sold a total of 8,053,500 shares of company stock worth $217,594,440 over the last quarter. 15.26% of the stock is currently owned by insiders.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
What are top analysts saying about Juno Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Juno Therapeutics Inc. and related companies.